European Randomised study of Screening for Prostate Cancer

Submission date Recruitment status Prospectively registered 20/12/2005 No longer recruiting [] Protocol [] Statistical analysis plan Registration date Overall study status 20/12/2005 Completed [X] Results Individual participant data **Last Edited** Condition category 30/10/2025 Cancer

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Mrs M. Roobol

Contact details

Erasmus Medical Center
Department of Urology
P.O. Box 2040
Rotterdam
Netherlands
3000 CA
+31 (0)10 4634548
m.roobol@erasmusmc.nl

Additional identifiers

Protocol serial number

NTR156

Study information

Scientific Title

European Randomised study of Screening for Prostate Cancer

Acronym

ERSPC

Study objectives

Screening causes a difference in prostate cancer mortality of 20% or more.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Local medical ethics committee gave approval

Study design

Multicentre randomised active-controlled parallel-group trial

Primary study design

Interventional

Study type(s)

Screening

Health condition(s) or problem(s) studied

Prostate cancer

Interventions

Prostate Specific Antigen (PSA) determination followed by Digital Rectal Examination (DRE) and prostate biopsy if PSA greater than or equal to 3.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

Prostate cancer mortality compared between the screened and the non-screened group of men at risk.

Key secondary outcome(s))

- 1. Progression-free (tumour free) survival
- 2. Survival free of metastatic disease
- 3. Quality of life in the screened and non-screened populations

Completion date

31/12/2010

Eligibility

Key inclusion criteria

Males aged 55 - 74 years (including age 74)

Patient Healthy volunteers allowed No Age group Senior Sex Male Key exclusion criteria Previous diagnosis of prostate cancer Date of first enrolment 01/10/1991 Date of final enrolment 31/12/2010 Locations Countries of recruitment Belgium Finland France Italy Netherlands Spain Sweden Switzerland

Participant type(s)

Study participating centre Erasmus Medical Center Rotterdam Netherlands 3000 CA

Sponsor information

Organisation

Erasmus Medical Centre (Netherlands)

ROR

https://ror.org/018906e22

Funder(s)

Funder type

Research organisation

Funder Name

The Netherlands Organisation for Health Research and Development (ZonMw) (Netherlands)

Funder Name

European Union (EU) (Belgium) - Fifth and Sixth Framework Programmes (FP5, FP6)

Funder Name

The National Cancer Fund (Koningin Wilhelmina Fonds [KWF]) (Netherlands)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient- facing?
Results article	results	26/03 /2009		Yes	No
Results article	results	01/08 /2011		Yes	No
Results article	results	01/05 /2012		Yes	No
	results	01/11			

Results article		/2012		Yes	No
Results article	results	01/02 /2014		Yes	No
Results article	results	01/08 /2015		Yes	No
Results article	European Study of Prostate Cancer Screening - 23- Year Follow-up	30/10 /2025	30/10 /2025	Yes	No
Other publications	11-year follow-up	15/03 /2012		Yes	No
Other publications	13-year follow-up	06/12 /2014		Yes	No
Participant information sheet	Participant information sheet	11/11 /2025	11/11 /2025	No	Yes
Study website	Study website	11/11 /2025	11/11 /2025	No	Yes